Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ITS
|
|||
| Former ID |
DIB015024
|
|||
| Drug Name |
ALN-VEG01
|
|||
| Synonyms |
RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Terminated | [1] | |
| Company |
Alnylam Pharmaceuticals Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025250) | |||
| REF 2 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.